Rituximab, developed in partnership by Roche and Biogen Idec, was the first anti-CD20 monoclonal antibody to be approved for the treatment of non-Hodgkin lymphomas. It works by specifically ...
In the case we report, this dilemma was resolved by successful treatment with rituximab. Rituximab has established benefit for the treatment of lupus and rheumatoid arthritis, for which it is ...
Most patients were able to stay with treatment once starting it, with retention rates of about 60% to 80% through 12 months (rituximab had the highest retention and IL-6 inhibitors the lowest).
Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.
A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events ...